(NASDAQ: PCRX) Pacira Biosciences's forecast annual revenue growth rate of 6.99% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Pacira Biosciences's revenue in 2024 is $681,754,000.On average, 8 Wall Street analysts forecast PCRX's revenue for 2024 to be $32,346,826,637, with the lowest PCRX revenue forecast at $31,887,369,610, and the highest PCRX revenue forecast at $32,823,412,647. On average, 8 Wall Street analysts forecast PCRX's revenue for 2025 to be $35,299,667,720, with the lowest PCRX revenue forecast at $34,370,606,606, and the highest PCRX revenue forecast at $36,315,304,670.
In 2026, PCRX is forecast to generate $38,991,708,180 in revenue, with the lowest revenue forecast at $35,996,463,556 and the highest revenue forecast at $41,238,025,282.